TIDMIXI

RNS Number : 3038P

IXICO plc

18 October 2021

IXICO plc

("IXICO" or the "Company")

Trading Update for year ended 30 September 2021

GBP9.2 million revenues outperform market expectations

EBITDA profitability expected to be materially ahead of market expectations

Strong GBP18.8 million order book and GBP6.7 million cash position

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces a trading update for the year ended 30 September 2021.

-- Full year revenue of GBP9.2 million (2020: GBP9.5 million) ahead of GBP8.7 million market expectations. Year-on-year revenue broadly flat despite full year of COVID-19 and lost revenue resulting from largest client's announcement on 23 March 2021 to cease dosing patients in its Huntington's Disease (HD) trials.

-- Year-end order book of GBP18.8 million (2020: GBP21.7 million), despite GBP7.1m adverse impact from the descoping of the above HD trials.

-- Year-end cash of GBP6.7 million, (2020: GBP7.9 million) reflecting more than GBP2 million technology investment to support long term growth (including our next generation, Microsoft Azure cloud-based, imaging data platform and proprietary AI data analytics platform). The Company continues to be debt-free.

-- Earnings before interest, tax, depreciation, and amortisation ('EBITDA') expected to be materially ahead of market expectations of GBP1.2 million and prior year (2020: GBP1.3 million). Key contributors include strong trading in the final quarter, careful management of discretionary costs and several positive one-time impacts.

Outlook

Benefiting from a strong order book, and an improving business outlook resulting from the initiation of new neuroimaging clinical trials during the 2022 financial year, the Company expects a return to revenue growth, albeit at a lower rate than recent historical levels. In the coming year, the Company will continue to pursue its investment plan to accelerate long-term sustained growth. Due to these investments, and the one-time beneficial impacts on EBITDA seen in 2021, the Company expects to see lower profitability in 2022.

The Company intends to announce its audited results for the year ended 30 September 2021 in early December 2021.

Giulio Cerroni, Chief Executive Officer of IXICO, commented: " 2021 has been another significant year in IXICO's development as a premium technology services partner to the global biopharmaceutical industry. Despite a challenging business environment, we announced contracts with several new clients, initiating early-stage clinical trials contracts across a widened range of neurological therapeutic indications. W e go into 2022 with an established track record of delivery, substantiated by a 25% 5-year revenue CAGR, a further year of growing profitability and a strengthened balance sheet.

"We recognise the potential for clients to prematurely terminate late-stage clinical trials as part of the inherent challenge of developing new treatments. However, with an ageing population and the high unmet clinical need for new treatments for neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, and other rarer neurological conditions, we remain very confident in the medium- and long-term opportunity for the scale up of our business.

"As we continue to build our commercial capabilities across the coming year to further diversify our order book, I am excited by the commercial partnerships, technology and operational investments we are making which position us, even more ready to maximise on the opportunity available to us."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)

For further information please contact:

 
 IXICO plc                                                             +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                                     +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                              +44 ( 0)20 7933 8780 or IXICO@walbrookpr.com 
 Paul McManus / Lianne Applegarth / 
  Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTBSBDGDBBDGBR

(END) Dow Jones Newswires

October 18, 2021 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Ixico.
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Ixico.